Healthcare [ 12/13 ] | Drug Manufacturers - Specialty & Generic [ 83/159 ]
NASDAQ | Common Stock
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
The company was incorporated in 1995 and is headquartered in Pearl River, New York.
On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S.
Bankruptcy Court for the Southern District of New York.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -225.81 Decreased by -2.68 K% | - |
| Nov 14, 23 | -7.16 Increased by +37.27% | - |
| Aug 9, 23 | -7.55 Increased by +86.42% | - |
| May 12, 23 | -13.83 Increased by +62.65% | - |
| Mar 9, 23 | 8.76 Increased by +125.25% | - |
| Nov 2, 22 | -11.41 Increased by +76.55% | - |
| Aug 5, 22 | -55.63 Decreased by -21.56% | - |
| May 12, 22 | -37.01 Increased by +47.61% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 37.98 M - | -217.76 M - | Decreased by -573.28% - |
| Sep 30, 23 | 27.71 M - | -8.89 M - | Decreased by -32.07% - |
| Jun 30, 23 | 29.68 M - | -9.38 M - | Decreased by -31.61% - |
| Mar 31, 23 | 22.26 M - | -16.82 M - | Decreased by -75.59% - |